23 studies found for:    TAK-700
Show Display Options
Rank Status Study
1 Completed Safety Study of TAK-700 in Subjects With Prostate Cancer.
Condition: Prostatic Neoplasms
Intervention: Drug: TAK-700
2 Active, not recruiting NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
Conditions: Prostatic Neoplasms;   Prostate Cancer
Intervention: Drug: TAK-700
3 Completed Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: orteronel 200mg/300mg;   Drug: orteronel 200mg/400mg;   Drug: Placebo
4 Suspended Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
Condition: Prostate Cancer
Interventions: Drug: Orteronel;   Drug: Placebo
5 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
6 Completed Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
Condition: Prostate Cancer
Intervention: Drug: TAK-700
7 Completed Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Orteronel+Prednisone
8 Recruiting Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Intervention: Drug: Orteronel
9 Suspended Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
Condition: Prostate Cancer
Interventions: Drug: Orteronel;   Drug: Placebo
10 Completed Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Docetaxel;   Drug: Prednisone
11 Recruiting CO11109: A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
Condition: Post Menopausal, Hormone Receptor Positive Breast Cancer
Intervention: Drug: TAK700
12 Withdrawn TAK-700 in Castration Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Orteronel;   Drug: Bicalutamide
13 Terminated Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: orteronel;   Other: laboratory biomarker analysis
14 Recruiting Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: orteronel;   Drug: triptorelin
15 Recruiting Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.
Condition: Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors
Intervention: Drug: Orteronel 300mg BID
16 Completed Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone;   Drug: Placebo + prednisone
17 Withdrawn Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)
Conditions: Prostate Cancer;   Castration-resistant Prostate Cancer
Interventions: Drug: Itraconazole;   Drug: Orteronel
18 Active, not recruiting Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone;   Drug: Placebo + prednisone
19 Recruiting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu Arteritis
Intervention:
20 Unknown  PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Conditions: Brain Ischemia;   Intracranial Hemorrhages
Interventions: Drug: Cilostazol;   Drug: Probucol;   Drug: Aspirin;   Drug: placebo of cilostazol;   Drug: placebo of aspirin;   Device: ankle-brachial index (ABI);   Device: intima-medial thickness (IMT);   Device: new asymptomatic brain hemorrhage;   Device: new ischemic lesions on follow-up FLAIR images

Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results
Indicates status has not been verified in more than two years